Exact FDA event identifier

Event 82676

1 recalled-product record grouped only because every row carries this exact official event ID.

Event summary

Timeline bucket: April 19, 2019
Product types: Drug
Classifications: Class II
Statuses: Terminated
Recalling firm wording: Pacifico National, Inc. dba AmEx Pharmacy

Dossier provenance

Source snapshots represented here

openFDA Drug Enforcement Report-date coverage June 20, 2012–July 08, 2026 Known gap: openFDA describes 2004-present coverage, but the current export has no report-date records in this interval.

Enforcement coverage uses report dates; product initiation dates can precede those bounds. Device-enrichment coverage uses FDA event_date_initiated.

How coverage and grouping work

Device root-cause evidence is not applicable to this event. No grouped product has the official product type device; this is not an unavailable-enrichment finding.

Complete imported group

Every recalled product in this event

1 official enforcement rows

Product dates, classifications, firms, and source wording remain attached to their individual rows. Opening this dossier never hides products that did not match a prior timeline filter.

drug · product 1 of 1

BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901 Lot:190212AB BUD:5/13/2019, Repackaged on 2/12/2019

D-1271-2019

Recall number: D-1271-2019
Initiated: April 19, 2019
Classification: Class II
Status: Terminated
Recalling firm: Pacifico National, Inc. dba AmEx Pharmacy
Quantity: 249 syringes

App-derived interpretation

Unknown reason.no_named_rule · v1.0.0

Defective Delivery System: difficult to express

These labels are deterministic app interpretations, not FDA categories.

Inspect official wording and provenance

Reason for recall

Defective Delivery System: difficult to express

Code information

Lot: 190212AB BUD: 5/13/2019

Distribution pattern

Nationwide in the US